Who we are

Acquisition of Pharmanoid

Inke expands its footprint with the acquisition of Pharmanoid, a specialized manufacturing site for High Potency Active Pharmaceutical Ingredients (HPAPIs) focused on ophthalmology.
This milestone strengthens Inke’s position in complex API development and marks the company’s entry into a new therapeutic area.

Acquisition by VC Keensight Capital

The latest in our series of strategic developments, Inke was acquired by venture capital firm Keensight Capital. This new chapter promises to leverage Keensight’s expertise in fostering high-growth potentials, focusing on further innovations and expanding our global reach. This acquisition set a new direction for our company’s future.

Plant Expansion to Increase Capacity for Inhalation APIs

We embarked on a significant expansion of our manufacturing plant to increase our production capacity for inhalation APIs. This expansion was driven by growing demand in the respiratory care market and aimed at enhancing our supply chain resilience.

Acquisition by Funds Advised by Permira

Continuing our trajectory of growth, Inke was acquired by funds advised by Permira. This partnership focused on bolstering our R&D capabilities and speeding up the commercialization of new products.

Spanish Health Authorities GMP inspection
(4th inspection)

Acquisition by Funds Advised by Apax

The acquisition by funds advised by Apax Partners was a key step in our journey, providing Inke with the capital to invest in cutting-edge technologies and expand our market presence globally.

FDA inspection (5th inspection)

Korean agency (KFDA) inspection

Our facility has successfully passed the inspection conducted by the Korean Food and Drug Administration (KFDA). This accomplishment highlights our adherence to rigorous regulatory standards and our commitment to delivering high-quality pharmaceutical products to the global market.

Spanish Health Authorities GMP inspection
(1st inspection)

Our facility successfully completed its first GMP inspection by the Spanish Health Authorities. This initial inspection marks a significant milestone, demonstrating our commitment to adhering to the highest standards of Good Manufacturing Practices and ensuring exceptional quality in our pharmaceutical products.

Acquisition by Invent Farma

A strategic milestone, Inke was acquired by Invent Farma, which expanded our resources and enabled further growth and expansion into new markets, enhancing our capabilities in drug development and production.

First FDA Inspection

Inke’s facilities passed their first U.S. Food and Drug Administration (FDA) inspection without any critical observations, a testament to our high standards of quality and compliance with stringent regulatory requirements.

ISO 14001 certification

Our facility proudly achieved ISO 14001 certification for environmental management. This longstanding certification underscores our long-term commitment to sustainable practices and our dedication to minimizing environmental impact through effective management systems. Maintaining this standard over the years has been crucial to our operational integrity and environmental responsibility.

Development of First Respiratory Product – Formoterol

Inke achieved a major milestone by developing its first respiratory product, which catered to a growing need in the healthcare sector for more effective respiratory medications. This development underlined our commitment to addressing critical health issues through innovation.

First Micronizer Installed – Loratadine

Marking a significant technological advancement, Inke installed its first micronizer. This equipment was pivotal in enhancing the precision and efficiency of our pharmaceutical formulations, setting a new standard in our production capabilities

Foundation of Inke S.A.

Inke S.A. was founded with a vision to innovate and lead in the pharmaceutical manufacturing industry, specializing initially in the production of generic active pharmaceutical ingredients.